Short on time ⌛️
⏩Need to skip ahead
⛔️1:48 ~ Barriers w traditional RCTs
🪜3:30 ~ Impact of market saturation &🌊 of new tx
🎯5:00 ~ Innovations in trial designs
🔮8:30 ~ MOAs of the future
💬12:45 ~ Pt communication & "how-to"
🤝17:10 ~ Establishing trust & inclusion
🎥 #MondayNightIBD webinar series starts NOW
@edloftus2 & @DCharabaty talk #IBD RCTs
⛔️Barriers to enrollment
🧩Innovative trial designs
🤝How to talk to pts about RCTs
🔮MOAs on the horizon
Check👇🏽 what’s in the future of #IBD 🧰
#IBDPoll1️⃣
🆓CME👉🏼https://t.co/IhU3NdfSPk
In your opinion/ experience, Which feature of the traditional RCT induction (drug vs PBO) + Re-randomize responders during maintenance- design mostly contributes to patient reluctance to enroll in RCT ?
#IBDPoll1️⃣
🆓CME👉🏼https://t.co/IhU3NdfSPk
In your opinion/ experience, Which feature of the traditional RCT induction (drug vs PBO) + Re-randomize responders during maintenance- design mostly contributes to patient reluctance to enroll in RCT ?
Don’t miss this 🧵 on anti-TL1A for #IBD#UC#Crohns!
We review the available data of the 3️⃣ upcoming agents for this 🆕 exciting MOA ! @DCharabaty@vipuljairath 👇🏽👇🏽👇🏽
@MondayNightIBD 1/ #MondayNightIBD#Back2Basics
TL1A , a 🆕🎯for inflammation & ?fibrosis
3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns
⚙️MOA, efficacy, safety
🆓CME 👉🏼https://t.co/nUZ8eFE9Dg
Support by an educational grant @Sanofi
📍Where are you in your career?
@MondayNightIBD 1/ #MondayNightIBD#Back2Basics
TL1A , a 🆕🎯for inflammation & ?fibrosis
3️⃣anti-TL1A mAbs w/ Ph 2 trials data +active Ph 3 for #UC & #Crohns
⚙️MOA, efficacy, safety
🆓CME 👉🏼https://t.co/nUZ8eFE9Dg
Support by an educational grant @Sanofi
📍Where are you in your career?
@MondayNightIBD@sanofi 2/ #MondayNightIBD
🚧~40% mod-sev #IBD have no or LoR to current Rx
🎯TL1A: TNF superfamily member, binds DR3 on T cells, NK cells & ILCs
🥊Drives inflammation (Th1/Th17/Th2) AND fibrosis (fibroblast activation)
🥊anti-TL1A block TL1A–DR3 →⬇️innate + adaptive immunity